KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Accured Expenses (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Change in Accured Expenses for 6 consecutive years, with $15.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 50.56% year-over-year to $15.8 million, compared with a TTM value of -$7.4 million through Dec 2025, down 234.21%, and an annual FY2025 reading of -$7.4 million, down 234.21% over the prior year.
  • Change in Accured Expenses was $15.8 million for Q4 2025 at Recursion Pharmaceuticals, up from -$8.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $15.8 million in Q4 2025 and bottomed at -$26.6 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $850950.0, with a median of $2.4 million recorded in 2022.
  • The sharpest move saw Change in Accured Expenses soared 1156.33% in 2021, then crashed 11680.0% in 2022.
  • Year by year, Change in Accured Expenses stood at $1.6 million in 2021, then soared by 641.26% to $12.2 million in 2022, then plummeted by 77.12% to $2.8 million in 2023, then skyrocketed by 278.01% to $10.5 million in 2024, then soared by 50.56% to $15.8 million in 2025.
  • Business Quant data shows Change in Accured Expenses for RXRX at $15.8 million in Q4 2025, -$8.0 million in Q3 2025, and $11.4 million in Q2 2025.